Related Experiment Video
Updated: Sep 5, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.0K
A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab
Angelo Ruggiero1, Wanda Lauro1, Gabriella Fabbrocini1
1Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.
Case Reports in Dermatology
|July 11, 2022
Summary
Circinate psoriasis, a rare pustular variant, often presents in childhood. This case highlights successful treatment with risankizumab (anti-IL-23) in a patient unresponsive to other therapies.
Area of Science:
- Dermatology
- Immunology
Background:
- Circinate psoriasis (Lapière) is a rare subtype of generalized subacute pustular psoriasis.
- It features annular lesions with peripheral micro-pustules, distinct from classic plaque psoriasis.
Observation:
- While often benign in childhood, circinate psoriasis can be recalcitrant, impacting quality of life.
- Previous systemic treatments and various biologic classes (anti-TNF, anti-IL-12/23, anti-IL-17) showed limited efficacy.
Findings:
- This report details the first case of circinate psoriasis successfully treated with risankizumab (an anti-IL-23 biologic).
- The patient was refractory to methotrexate and multiple other biologic agents.
Implications:
- Risankizumab offers a potential therapeutic option for severe, treatment-resistant circinate psoriasis.
- Further research is warranted to explore the efficacy of IL-23 inhibitors in this rare psoriasis subtype.
